CEO Mattias Perjos credited the company's performance to successful product launches and operational efficiency. Acute Care Therapies saw broad gains, while the Sterile Transfer category achieved double-digit growth. Excluding the impact of the tariff refund and currency fluctuations, the adjusted EBITA margin stood at 15.2%, reflecting steady productivity improvements and favorable product mix.

Innovation remains a cornerstone of the company’s strategy, evidenced by the release of new endoscopic vessel harvesting technology and automated endoscope reprocessing systems. In June, the company reached a regulatory milestone by submitting a 510(k) application for its Cardiosave intra-aortic balloon pump to the FDA. To bolster its market position, Getinge also acquired the UK-based distributor Pennamed and opened a new digital perioperative innovation center in Hamburg. Given current customer demand, leadership maintains its forecast for 3–5% organic sales growth for the full year.